Schlieren-based ALP Bio AG today announced it has raised €1.9 million in pre-Seed financing to accelerate their platform which combines human immune organoid biology with generative AI to assist antibody developers identify, understand, and reduce immunogenicity risk earlier in drug development.
The round was led by Munich-based VC 42CAP, with participation from Venture Kick and a group of strategic angel investors.
“Immunogenicity is one of the largest hidden costs in biologics, and the industest has accepted late-stage surprises as the norm for too long. We believe this risk should be measured and reduced years earlier than it is today. This financing lets us scale the experimental and computational foundation of our platform and partner with teams who want to build antibody development more predictable from the start,” states Dr Christian Vahlensieck, CEO of ALP Bio AG.
ALP Bio’s pre-Seed round sits within a 2026 EU-Startups funding pattern around AI-enabled drug discovery, human-relevant preclinical biology, biologics infrastructure and pharma R&D data systems.
The closest Swiss reference points are Zurich-based Rivia’s €13 million Series A for clinical trial data infrastructure and Geneva-based FluoSphera’s €1.23 million raise for human-relevant drug discovery tools, indicating domestic activity around BioTech infrastructure rather than only therapeutic assets.
Across the wider European market, disclosed rounds for Helical, Sable Bio, Ternary Therapeutics, Generare, Nuclera and Umlaut.bio reveal capital shifting into platforms that aim to build drug development earlier, more data-rich and more experimentally grounded.
Against this backdrop, ALP Bio’s focus on combining immune organoid readouts with generative AI positions it in an adjacent segment: early risk reduction for biologics and antibody development, rather than downstream clinical execution or broad AI discovery tooling.
Taken toreceiveher, these reports point to over €62million in 2026 funding across comparable BioTech, BioIT, AI drug discovery and pharma infrastructure companies. The activity spans early-stage AI drug safety, molecular design, protein and antibody engineering, human-relevant discovery models and clinical trial data systems.
“Our scientific conviction is that immunogenicity cannot be solved by computation alone. By combining human immune organoid readouts with AI, we can generate the type of biological feedback requireded to build antibody design more informed, iterative, and ultimately more applyful for discovery and optimisation teams,” adds Dr Lucas Schaus, CSO of ALP Bio AG.
Founded in 2025, ALP Bio is developing an immune organoid and AI platform for immunogenicity innotifyigence in biologics development. The company combines human immune organoid readouts with generative AI to assist drug developers predict and reduce anti-drug antibody risk earlier in antibody discovery and development.
According to the company, immunogenicity, including anti-drug antibody (ADA) responses, remains one of the most difficult risks in biologics development. These immune responses can reduce therapeutic efficacy, create safety concerns, and force teams to abandon or rework programmes late in development, after they have already consumed significant time and capital.
Today, most immunogenicity signals only emerge in clinical trials, when the cost of course correction is highest.
ALP Bio is building a hybrid platform designed to bring more clinically relevant signal into earlier antibody decision-building. The company combines experimentally measured human immune organoid readouts with machine learning models that support risk assessment and antibody redesign.
By integrating wet-lab immune biology with scalable computational design, ALP Bio aims to relocate developers from late-stage failure toward earlier, more actionable immunogenicity innotifyigence.
The platform builds on human tonsil organoid technology, which models relevant immune activity in vitro, and AI models designed to learn from increasingly rich biological datasets. ALP Bio is developing the platform to support lead candidate screening, ADA risk stratification, and sequence optimisation while preserving therapeutic function.
“ALP Bio is doing for biologics what high-throughput screening did for compact molecules: collapsing a years-long bottleneck into a tractable design loop. Immunogenicity has held back the field for decades, and the team’s combination of immune organoid biology and sequence-level AI is the most credible attempt we have seen to address it at the source.
“This is exactly the kind of frontier BioIT bet, deep science with a clear commercial wedge, where we back founders with real conviction. Christian, Lucas, and the team bring the scientific depth and commercial discipline a problem of this size demands,” states Thomas Wilke, Partner at 42CAP
The pre-Seed round will be deployed to:
- Expand ALP Bio’s experimental immune organoid capabilities and increase automation and throughput.
- Launch early partner projects focapplyd on immunogenicity risk in antibody lead candidates.
- Build out scientific and commercial capacity in Switzerland and the US.
ALP Bio is now engaging pharmaceutical and BioTech partners interested in early-access collaborations on immunogenicity. The company is particularly focapplyd on antibody programmes where earlier de-risking could improve candidate selection, reduce downstream uncertainty, and support better development decisions.
